Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 15/20 | 0.52 |
| ▸ | HTR2B | P41595 | 15/20 | 0.52 |
| ▸ | HTR2A | P28223 | 14/20 | 0.52 |
| ▸ | HTR7 | P34969 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1476212 | 0.85 | HTR2C (0.49) | HTR2CHTR2BHTR2AHTR7HTR1A | |
| SCHEMBL2077015 | 0.82 | HTR7 (0.68) | HTR2CHTR2BHTR2AHTR7HTR1A | |
| SCHEMBL1475739 | 0.82 | HTR2C (0.53) | HTR2CHTR2BHTR2AHTR7HTR1A | |
| SCHEMBL1476677 | 0.81 | HTR2C (0.59) | HTR2CHTR2BHTR2AHTR7HTR1A | |
| SCHEMBL1475046 | 0.81 | HTR2A (0.65) | HTR2CHTR2BHTR2AHTR7HTR1A | |
| SCHEMBL1477936 | 0.78 | HTR2C (0.53) | HTR2CHTR2BHTR2AHTR7HTR1A | |
| SCHEMBL2074756 | 0.78 | KDM1A (0.44) | — | |
| SCHEMBL1476402 | 0.77 | HTR2A (0.50) | HTR2CHTR2BHTR2AHTR7HTR1A | |
| SCHEMBL1476628 | 0.77 | HTR2A (0.75) | HTR2CHTR2BHTR2AHTR7HTR1A | |
| SCHEMBL2077369 | 0.75 | HTR2C (0.52) | HTR2CHTR2BHTR2AHTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1905774-B1 | Fused heterocyclic compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-20 | — | — | EP | claimed |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-17 | — | — | US | claimed |
| EP-2016064-B1 | METHODS FOR THE PREPARATION OF PYRAZOLE-CONTAINING COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-03 | — | — | EP | claimed |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | US | claimed |
| EP-2016064-A2 | METHODS FOR THE PREPARATION OF PYRAZOLE-CONTAINING COMPOUNDS | Janssen Pharmaceutica, N.V. (BE) | 2009-01-21 | — | — | EP | claimed |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | claimed |
| EP-1905774-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-04-02 | — | — | EP | claimed |
| WO-2007131153-A2 | METHODS FOR THE PREPARATION OF PYRAZOLE-CONTAINING COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | WO | claimed |
| US-20070260057-A1 | METHODS FOR THE PREPARATION OF PYRAZOLE-CONTAINING COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-08 | — | — | US | claimed |
| EP-1905774-B1 | Fused heterocyclic compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-20 | — | — | EP | disclosed |
| EP-1905774-B1 | Fused heterocyclic compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-20 | — | — | EP | disclosed |
| US-7915404-B2 | Methods for the preparation of pyrazole-containing compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-7897771-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| US-7897771-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| EP-1905774-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007131153-A2 | METHODS FOR THE PREPARATION OF PYRAZOLE-CONTAINING COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070260057-A1 | METHODS FOR THE PREPARATION OF PYRAZOLE-CONTAINING COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-08 | — | — | US | disclosed |
| EP-1668014-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-14 | — | — | EP | disclosed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005040169-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | HTR2C 5/4885HTR2B 13/4885HTR2A 9/4885 |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | HTR2C 5/4885HTR2B 13/4885HTR2A 9/4885 |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | HTR2C 5/4885HTR2B 13/4885HTR2A 9/4885 |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | HTR2C 5/4885HTR2B 13/4885HTR2A 9/4885 |
| US-20070260057-A1 | METHODS FOR THE PREPARATION OF PYRAZOLE-CONTAINING COMPOUNDS | HTR3C, HTR3A, HTR3B | HTR2C 8/4885HTR2B 14/4885HTR2A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.